Annuncio pubblicitario
Italia markets close in 53 minutes

  • FTSE MIB

    33.901,83
    +20,33 (+0,06%)
     

  • Dow Jones

    37.924,79
    +149,41 (+0,40%)
     

  • Nasdaq

    15.448,28
    -153,22 (-0,98%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,12
    +0,39 (+0,47%)
     

  • Bitcoin EUR

    60.283,45
    +627,63 (+1,05%)
     

  • CMC Crypto 200

    1.375,54
    +62,91 (+5,04%)
     

  • Oro

    2.402,50
    +4,50 (+0,19%)
     

  • EUR/USD

    1,0673
    +0,0027 (+0,26%)
     

  • S&P 500

    4.995,97
    -15,15 (-0,30%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.925,82
    -10,75 (-0,22%)
     

  • EUR/GBP

    0,8573
    +0,0017 (+0,20%)
     

  • EUR/CHF

    0,9695
    -0,0016 (-0,16%)
     

  • EUR/CAD

    1,4653
    +0,0003 (+0,02%)
     

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

Cara Therapeutics, Inc.
·1 minuto per la lettura
Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com